Navigation Links
New artemisinin-based treatment against malaria promising
Date:11/8/2011

ANTWERP For some time now, artemisinin, derived from a Chinese herb, has been the most powerful treatment available against malaria. To avoid the malaria parasite becoming resistant, the World Health Organisation (WHO) strongly recommends combining artemisinin with another anti-malarial drug. But there are different formulations and derivatives, in different combinations and with dosing schemes. Scientists from the Institute of Tropical Medicine (ITM) carried out a head-to-head comparison of four combination therapies in seven African countries. One combination appeared particularly promising for regions where the risk of re-infection is high.

Malaria is caused by several related parasites, of which Plasmodium falciparum is the worst. The parasites have a complicated life cycle, partly in mosquitoes. When an infected mosquito bites a human, parasites are injected with the mosquito saliva into the blood, travel to the liver, where they change form, then infect red blood cells, where they further reproduce. After a few days (depending on the parasite species), the red blood cells burst to release a huge number of new parasites. These bursts cause intense fever, anaemia, renal problems. Each year, about 800 000 people die of malaria.

In recent years, the burden of malaria has declined substantially in several sub-Saharan African countries, due to large scale indoor residual spraying of insecticides, massive distribution of insecticide-treated bed nets, and the introduction of artemisinin-based combination treatments, ACTs for short. To treat patients with malaria the WHO advises each region to choose an ACT based on the local level of resistance to non-artemisinin medicine in the combination. But data on that resistance are scarce.

The ITM scientists, who also took part in the recent trials of the first effective malaria vaccine, compared four ACT treatments, in more than 4 000 randomised children less than 5 years of age with uncomplicated malaria, in twelve sites distributed in seven sub-Saharan African countries. This is the largest such study on ACT ever done in Africa. Three of the regimes had excellent and similar efficacy in treating the malaria attack, but of those, treatment with combination dihydroartemisinin-piperaquine (the combination most recent recommended by the WHO) resulted in significantly fewer recurrent infections. The development of resistance should be closely monitored, the scientists advise, but this new therapy clearly shows great promise.


'/>"/>

Contact: Umberto D'Alessandro
udalessandro@mrc.gm
220-717-9580
Institute of Tropical Medicine Antwerp
Source:Eurekalert

Related medicine news :

1. New Bypass Surgery for Stroke Riskier Than Drug Treatment
2. Northern Ireland company makes major breakthrough in cancer treatment
3. Major project to implement new treatments to boost kala-azar elimination strategies
4. Study identifies factors linked with better medication response for treatment of juvenile arthritis
5. More Targeted Treatments Key to Progress in War on Cancer: Report
6. Wayne State therapeutic marijuana use study could impact state policies, guide treatment
7. Gene therapy shows promise as hemophilia treatment in animal studies
8. Researchers reveal potential treatment for sickle cell disease
9. ASU leads $5 million NIH-sponsored research initiative to advance diabetes care and treatment
10. New research on improved treatment options and screening strategies for Hepatitis C
11. Folate receptors may serve as a front door to ovarian cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... (PRWEB) , ... April 30, 2017 , ... PracticeMatch, a ... increase in projected attendance for this year’s physician career fairs, with this year’s RSVPs ... complete schedule for the 2017 calendar year of national physician career fairs is located ...
(Date:4/29/2017)... S.C. (PRWEB) , ... April ... ... Southeast’s leading software and web development company, today announced the launch of ... DonorBridge is a solution combining decades of software innovation and industry expertise ...
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
(Date:4/29/2017)... ... April 29, 2017 , ... Sterling Global Products ... fine retailers selling biodegradable, hanging flushable wipes dispensers and/or 42 count refill packs ... in San Antonio, Texas, operates more than 350 stores throughout Texas and expanding ...
(Date:4/29/2017)... ... April 29, 2017 , ... ... and recognize the positive impact veterinarians have on animal health and welfare as ... Organization for Animal Health (OIE) choose a theme each year and this year ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... Halo Labs announces the launch of a ... called the Horizon at PEGS 2017 in ... analyzes sub visible particulate matter in biopharmaceutical samples to ... early as candidate selection and pre-formulation. Halo ... organization Elion Labs for system validation. "We ...
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
Breaking Medicine Technology: